The Stanford Study That’s Changing Everything We Know About Ibogaine

For decades, ibogaine existed on the fringes — used quietly in Mexico and a handful of other countries, discussed in hushed tones by addiction medicine researchers who believed in its potential but had almost no government-funded data to point to. That changed in 2025, when a team of Stanford Medicine researchers published a landmark study in Nature Medicine that sent shockwaves through the addiction treatment and mental health communities.

What the Stanford Ibogaine Study Found

The study examined 30 special operations veterans — men and women who had served in the most demanding combat and special operations roles the U.S. military fields. Many had survived multiple deployments, traumatic brain injuries, and the kind of psychological stress that conventional treatment has struggled to address. Every participant had PTSD, depression, anxiety, or some combination of the three. Most had tried conventional treatment with limited success.

After a single ibogaine treatment session at a clinic in Mexico, the results at one-month follow-up were:

• PTSD symptoms reduced by 88% (Cherian et al., Nature Medicine, 2024 · observational, no control group, n=30)
• Depression reduced by 87%
• Anxiety reduced by 81%
• Disability ratings improved significantly
• Cognitive function scores improved
• Suicidal ideation substantially reduced

Why These Numbers Matter

SSRIs and SNRIs — the most commonly prescribed antidepressants — typically reduce depression symptom scores by 20–30% in clinical trials. Prolonged Exposure therapy and Cognitive Processing Therapy, the two gold-standard psychotherapy approaches for PTSD, produce meaningful improvements but require weeks to months of intensive work and are not effective for everyone. Ibogaine, in a single treatment experience lasting 24–36 hours, produced an 88% (Cherian et al., Nature Medicine, 2024 · observational, no control group, n=30) reduction in PTSD and an 87% reduction in depression — sustained at one-month follow-up — in a population that had largely exhausted other options.

The lead author, Dr. Nolan Williams, described the results as “the most dramatic change in PTSD we’ve ever seen in any clinical trial.”

How Does Ibogaine Produce These Effects?

The Stanford study identified several key mechanisms: ibogaine promotes neuroplasticity by increasing BDNF (brain-derived neurotrophic factor), it acts on multiple receptor systems simultaneously (opioid, serotonin, dopamine, NMDA, and sigma receptors), and the 24–36 hour psychological experience itself appears to play a therapeutic role distinct from the pharmacology alone. Ibogaine’s metabolite noribogaine also has a long half-life, continuing to exert stabilizing effects in the brain for weeks following the acute experience.

The Political Response

In April 2026, President Trump signed an executive order directing the FDA to fast-track review of psychedelic treatments including ibogaine, and allocating $50 million toward making these treatments accessible to veterans. FDA Commissioner Dr. Marty Makary specifically cited the Stanford study’s findings as part of the rationale for accelerating the review process.

What This Means for Patients Today

The Stanford study does not change ibogaine’s current legal status in the United States — it remains Schedule I. But it provides scientific validation at the highest level and creates momentum toward eventual U.S. legalization. It confirms what thousands of patients who have already undergone ibogaine treatment in Mexico have been saying for years: this is not fringe medicine. It is a pharmacologically serious intervention with measurable, significant effects on some of the most treatment-resistant conditions in psychiatry and addiction medicine.